Namkyun Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Namkyun Kim has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
- Cheol Whan Lee
Division of Cardiology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
5 shared publications - Bo Eun Park
Kyungpook National University Hospital
4 shared publications - Chang-Wook Nam
Department of Medicine, Keimyung University Dongsan Medical Center, Daegu, Korea
4 shared publications - Dong Heon Yang
Division of Cardiology, Department of Internal Medicine, Kyungpook National University, Daegu, Korea
4 shared publications - Doyeon Hwang
Department of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
4 shared publications - Hong Nyun Kim
Kyungpook National University Hospital
4 shared publications
Latest Publications
- Open Access
- 18 August 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Real-world data for optimal single antiplatelet therapy during the chronic maintenance period after percutaneous coronary intervention: a nationwide study of Korea
- 18 August 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessReal-world data for optimal single antiplatelet therapy during the chronic maintenance period after percutaneous coronary intervention: a nationwide study of Korea
- Open Access
- 10 June 2026
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 26 (1)
Age-dependent associations of high-intensity statin therapy with 3-year clinical outcomes after acute myocardial infarction: longitudinal LDL-C profiles in a nationwide registry
High-intensity statin therapy is an important strategy for secondary prevention after acute myocardial infarction (AMI), but its clinical benefit in very elderly patients remains uncertain. We aimed to evaluate whether the association of high-intensity statins with clinical outcomes differs by age in older AMI patients undergoing percutaneous coronary intervention (PCI). Using the Korean Acute Myocardial Infarction Registry-National Institutes of Health (KAMIR-NIH), we compared outcomes of high-intensity versus non-high-intensity statins among 4,147 patients aged ≥ 65 years treated with PCI and discharged on statins, stratified by age (65-74 years, n = 2,316; ≥75 years, n = 1,831), in overall and propensity score-matched cohorts (matched on age, sex, body mass index, Killip class, comorbidities, left ventricular ejection fraction, estimated glomerular filtration rate, baseline LDL-C, discharge medications, and procedural characteristics). The primary endpoint was 3-year major adverse cardiovascular events (MACE: all-cause death, recurrent myocardial infarction, or any coronary revascularization); the death/MI composite was a key secondary outcome. Post-discharge statin persistence, LDL-C target attainment, and longitudinal LDL-C profiles were additionally examined. High-intensity statins were prescribed at discharge in 748 (32.3%) patients aged 65-74 years and 520 (28.4%) aged ≥ 75 years. In the 65-74-year group, high-intensity statins were associated with lower risks of MACE (overall cohort: 13.6% vs. 18.9%, adjusted HR 0.69, 95% CI 0.55-0.87, p < 0.01; matched: 13.7% vs. 18.1%, HR 0.71, 95% CI 0.54-0.92, p = 0.01) and the death/MI composite (overall: 7.9% vs. 11.3%, adjusted HR 0.69, 95% CI 0.51-0.94, p = 0.01; matched: 8.0% vs. 10.9%, HR 0.70, 95% CI 0.49-0.99, p = 0.04). In patients aged ≥ 75 years, neither composite outcome showed a statistically evident association with statin intensity. Post-discharge high-intensity statin persistence was comparable by age. Measured-only LDL-C < 70 mg/dL attainment was similar between age groups within each statin-intensity stratum, but when missing values were treated as non-attainment, lower attainment emerged in patients aged ≥ 75 years compared with those aged 65-74 years within each statin-intensity stratum, paralleling lower follow-up measurement rates. LDL-C separation and reductions in variability were also less distinct in this age group. Discharge high-intensity statin therapy was associated with lower risks of the principal composite outcomes in patients aged 65-74 years but not in those aged ≥ 75 years. In very elderly patients, this attenuation may reflect residual geriatric confounding, incomplete LDL-C ascertainment, and uncertainty in sustained treatment exposure rather than absence of benefit, underscoring the need for prospective evaluation of target-oriented strategies in this population.
- 10 June 2026
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 26 (1)
Open AccessAge-dependent associations of high-intensity statin therapy with 3-year clinical outcomes after acute myocardial infarction: longitudinal LDL-C profiles in a nationwide registry
High-intensity statin therapy is an important strategy for secondary prevention after acute myocardial infarction (AMI), but its clinical benefit in very elderly patients remains uncertain. We aimed to evaluate whether the association of high-intensity statins with clinical outcomes differs by age in older AMI patients undergoing percutaneous coronary intervention (PCI). Using the Korean Acute Myocardial Infarction Registry-National Institutes of Health (KAMIR-NIH), we compared outcomes of high-intensity versus non-high-intensity statins among 4,147 patients aged ≥ 65 years treated with PCI and discharged on statins, stratified by age (65-74 years, n = 2,316; ≥75 years, n = 1,831), in overall and propensity score-matched cohorts (matched on age, sex, body mass index, Killip class, comorbidities, left ventricular ejection fraction, estimated glomerular filtration rate, baseline LDL-C, discharge medications, and procedural characteristics). The primary endpoint was 3-year major adverse cardiovascular events (MACE: all-cause death, recurrent myocardial infarction, or any coronary revascularization); the death/MI composite was a key secondary outcome. Post-discharge statin persistence, LDL-C target attainment, and longitudinal LDL-C profiles were additionally examined. High-intensity statins were prescribed at discharge in 748 (32.3%) patients aged 65-74 years and 520 (28.4%) aged ≥ 75 years. In the 65-74-year group, high-intensity statins were associated with lower risks of MACE (overall cohort: 13.6% vs. 18.9%, adjusted HR 0.69, 95% CI 0.55-0.87, p < 0.01; matched: 13.7% vs. 18.1%, HR 0.71, 95% CI 0.54-0.92, p = 0.01) and the death/MI composite (overall: 7.9% vs. 11.3%, adjusted HR 0.69, 95% CI 0.51-0.94, p = 0.01; matched: 8.0% vs. 10.9%, HR 0.70, 95% CI 0.49-0.99, p = 0.04). In patients aged ≥ 75 years, neither composite outcome showed a statistically evident association with statin intensity. Post-discharge high-intensity statin persistence was comparable by age. Measured-only LDL-C < 70 mg/dL attainment was similar between age groups within each statin-intensity stratum, but when missing values were treated as non-attainment, lower attainment emerged in patients aged ≥ 75 years compared with those aged 65-74 years within each statin-intensity stratum, paralleling lower follow-up measurement rates. LDL-C separation and reductions in variability were also less distinct in this age group. Discharge high-intensity statin therapy was associated with lower risks of the principal composite outcomes in patients aged 65-74 years but not in those aged ≥ 75 years. In very elderly patients, this attenuation may reflect residual geriatric confounding, incomplete LDL-C ascertainment, and uncertainty in sustained treatment exposure rather than absence of benefit, underscoring the need for prospective evaluation of target-oriented strategies in this population.
- Open Access
- 1 April 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83 (4) , e25810
Low-Dose TEL/AML/CHTD SPC Versus Standard-Dose TEL in Hypertension: Phase III RCT
BACKGROUND: Although low-dose triple single-pill combination therapies show promising efficacy and safety, studies comparing them to standard-dose monotherapies remain limited. This phase III, randomized, double-blind trial evaluated the efficacy and safety of a low-dose single-pill combination of telmisartan, amlodipine, and chlorthalidone versus standard-dose telmisartan monotherapy in patients with essential hypertension. METHODS: After a 4-week placebo run-in period, 314 eligible subjects were randomized to either receive telmisartan/amlodipine/chlorthalidone 20/2.5/6.25 mg or telmisartan 40 mg for 8 weeks. The primary efficacy end point was the change in mean sitting systolic blood pressure from baseline to week 8, with noninferiority assessed in the per-protocol set (PPS), followed by superiority testing in the full analysis set using a gatekeeping approach to control for type I error. RESULTS: At week 8, the combination group demonstrated significant mean sitting systolic blood pressure reduction compared with monotherapy in the per-protocol set analysis (least squares mean difference, −3.8 mm Hg [95% CI: −6.7 to −0.9]; P =0.01), establishing its noninferiority. Furthermore, the superiority of the combination therapy was confirmed in the full analysis set (LS mean difference, −4.0 mm Hg [95% CI, −6.8 to −1.3]; P P <0.01). Subgroup analyses showed consistent efficacy across clinical strata, including age and prior antihypertensive treatment. The incidence of adverse events was comparable between groups, with no serious drug-related events reported. CONCLUSIONS: Low-dose triple single-pill combination of telmisartan/amlodipine/chlorthalidone demonstrated superior BP-lowering efficacy with well-tolerated and comparable safety to standard-dose telmisartan monotherapy. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06348576.
- 1 April 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83 (4) , e25810
Open AccessLow-Dose TEL/AML/CHTD SPC Versus Standard-Dose TEL in Hypertension: Phase III RCT
BACKGROUND: Although low-dose triple single-pill combination therapies show promising efficacy and safety, studies comparing them to standard-dose monotherapies remain limited. This phase III, randomized, double-blind trial evaluated the efficacy and safety of a low-dose single-pill combination of telmisartan, amlodipine, and chlorthalidone versus standard-dose telmisartan monotherapy in patients with essential hypertension. METHODS: After a 4-week placebo run-in period, 314 eligible subjects were randomized to either receive telmisartan/amlodipine/chlorthalidone 20/2.5/6.25 mg or telmisartan 40 mg for 8 weeks. The primary efficacy end point was the change in mean sitting systolic blood pressure from baseline to week 8, with noninferiority assessed in the per-protocol set (PPS), followed by superiority testing in the full analysis set using a gatekeeping approach to control for type I error. RESULTS: At week 8, the combination group demonstrated significant mean sitting systolic blood pressure reduction compared with monotherapy in the per-protocol set analysis (least squares mean difference, −3.8 mm Hg [95% CI: −6.7 to −0.9]; P =0.01), establishing its noninferiority. Furthermore, the superiority of the combination therapy was confirmed in the full analysis set (LS mean difference, −4.0 mm Hg [95% CI, −6.8 to −1.3]; P P <0.01). Subgroup analyses showed consistent efficacy across clinical strata, including age and prior antihypertensive treatment. The incidence of adverse events was comparable between groups, with no serious drug-related events reported. CONCLUSIONS: Low-dose triple single-pill combination of telmisartan/amlodipine/chlorthalidone demonstrated superior BP-lowering efficacy with well-tolerated and comparable safety to standard-dose telmisartan monotherapy. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06348576.
- Open Access
- 17 March 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (6) , e045151
Long‐Term Clinical Outcomes of Acute Myocardial Infarction Based on Institutional Experience With IVUS
Background: Intravascular ultrasound (IVUS)‐guided percutaneous coronary intervention improves patient outcomes, yet the impact of a center's IVUS experience on long‐term outcomes remains unclear. We evaluated whether the prognostic association of IVUS‐guided percutaneous coronary intervention in patients with acute myocardial infarction differs based on a center's level of IVUS use. Methods: We retrospectively analyzed 9752 patients with acute myocardial infarction treated with second‐generation drug‐eluting stents from the KAMIR‐NIH (Korean Acute Myocardial Infarction Registry–National Institutes of Health). The primary outcome was 3‐year major adverse cardiovascular events, defined as a composite of all‐cause death, myocardial infarction, and coronary revascularization. The secondary outcome was target‐lesion failure, defined as a composite of cardiac death, target‐vessel myocardial infarction, and ischemia‐driven target lesion revascularization. Centers were classified into higher‐ or lower‐IVUS‐use groups on the basis of median institutional usage (10.3%). Results: In higher‐use centers, IVUS‐guided percutaneous coronary intervention was associated with lower rates of major adverse cardiovascular events (15.3% versus 18.5%, P =0.016) and target‐lesion failure (6.3% versus 8.3%, P =0.039) in propensity score–matched populations. Multivariate Cox analysis confirmed lower risks of major adverse cardiovascular events (hazard ratio [HR], 0.80 [95% CI, 0.69–0.93]; P =0.003) and target‐lesion failure (HR, 0.75 [95% CI, 0.59–0.93]; P =0.01). Conversely, in lower‐use centers, IVUS guidance was not associated with significant differences in major adverse cardiovascular events (15.7% versus 18.6%, P =0.422) or target‐lesion failure (8.9% versus 10.4%, P =0.644). Conclusions: The association of IVUS‐guided percutaneous coronary intervention with lower adverse event rates was more apparent and statistically demonstrable in centers with higher IVUS use. These findings suggest that institutional experience may amplify the observable impact of IVUS guidance, underscoring the potential value of standardized IVUS implementation in acute myocardial infarction management.
- 17 March 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (6) , e045151
Open AccessLong‐Term Clinical Outcomes of Acute Myocardial Infarction Based on Institutional Experience With IVUS
Background: Intravascular ultrasound (IVUS)‐guided percutaneous coronary intervention improves patient outcomes, yet the impact of a center's IVUS experience on long‐term outcomes remains unclear. We evaluated whether the prognostic association of IVUS‐guided percutaneous coronary intervention in patients with acute myocardial infarction differs based on a center's level of IVUS use. Methods: We retrospectively analyzed 9752 patients with acute myocardial infarction treated with second‐generation drug‐eluting stents from the KAMIR‐NIH (Korean Acute Myocardial Infarction Registry–National Institutes of Health). The primary outcome was 3‐year major adverse cardiovascular events, defined as a composite of all‐cause death, myocardial infarction, and coronary revascularization. The secondary outcome was target‐lesion failure, defined as a composite of cardiac death, target‐vessel myocardial infarction, and ischemia‐driven target lesion revascularization. Centers were classified into higher‐ or lower‐IVUS‐use groups on the basis of median institutional usage (10.3%). Results: In higher‐use centers, IVUS‐guided percutaneous coronary intervention was associated with lower rates of major adverse cardiovascular events (15.3% versus 18.5%, P =0.016) and target‐lesion failure (6.3% versus 8.3%, P =0.039) in propensity score–matched populations. Multivariate Cox analysis confirmed lower risks of major adverse cardiovascular events (hazard ratio [HR], 0.80 [95% CI, 0.69–0.93]; P =0.003) and target‐lesion failure (HR, 0.75 [95% CI, 0.59–0.93]; P =0.01). Conversely, in lower‐use centers, IVUS guidance was not associated with significant differences in major adverse cardiovascular events (15.7% versus 18.6%, P =0.422) or target‐lesion failure (8.9% versus 10.4%, P =0.644). Conclusions: The association of IVUS‐guided percutaneous coronary intervention with lower adverse event rates was more apparent and statistically demonstrable in centers with higher IVUS use. These findings suggest that institutional experience may amplify the observable impact of IVUS guidance, underscoring the potential value of standardized IVUS implementation in acute myocardial infarction management.
- Open Access
- 1 January 2026
- Published by XMLink in Korean Circulation Journal
- Vol. 56 (7) , 562-586
Korean Society of Interventional Cardiology Expert Consensus for the Management of Chronic Coronary Syndrome: Part 2
Revascularization remains an important component of chronic coronary syndrome (CCS) management, particularly in patients with high-risk coronary anatomy, impaired left ventricular (LV) function, or persistent symptoms despite guideline-directed medical therapy. Evidence indicates that prognostic benefit is most pronounced in patients with left main disease, multivessel disease, proximal left anterior descending artery involvement, and severe LV systolic dysfunction. In other patients, revascularization primarily improves angina symptoms and quality of life. The choice between percutaneous coronary intervention (PCI) and coronary artery bypass grafting should be individualized according to coronary anatomy, clinical risk, comorbidities, and the likelihood of complete revascularization. Contemporary PCI increasingly incorporates coronary physiology and intravascular imaging to refine lesion selection and improve procedural outcomes. Long-term CCS management requires structured follow-up to detect disease progression, recurrent ischemia, revascularization failure, and cardiovascular complications. Routine surveillance testing is not recommended in asymptomatic patients after PCI. Instead, follow-up should be tailored to patient risk and clinical status. When complete revascularization fails, mechanisms such as stent thrombosis, in-stent restenosis, graft failure, and progression of untreated coronary disease should be identified; intravascular imaging has an important role in guiding repeat revascularization. Comprehensive CCS management should also address complications, including heart failure, ventricular arrhythmias, and secondary valvular disease, through a multidisciplinary, patient-centered approach.
- 1 January 2026
- Published by XMLink in Korean Circulation Journal
- Vol. 56 (7) , 562-586
Open AccessKorean Society of Interventional Cardiology Expert Consensus for the Management of Chronic Coronary Syndrome: Part 2
Revascularization remains an important component of chronic coronary syndrome (CCS) management, particularly in patients with high-risk coronary anatomy, impaired left ventricular (LV) function, or persistent symptoms despite guideline-directed medical therapy. Evidence indicates that prognostic benefit is most pronounced in patients with left main disease, multivessel disease, proximal left anterior descending artery involvement, and severe LV systolic dysfunction. In other patients, revascularization primarily improves angina symptoms and quality of life. The choice between percutaneous coronary intervention (PCI) and coronary artery bypass grafting should be individualized according to coronary anatomy, clinical risk, comorbidities, and the likelihood of complete revascularization. Contemporary PCI increasingly incorporates coronary physiology and intravascular imaging to refine lesion selection and improve procedural outcomes. Long-term CCS management requires structured follow-up to detect disease progression, recurrent ischemia, revascularization failure, and cardiovascular complications. Routine surveillance testing is not recommended in asymptomatic patients after PCI. Instead, follow-up should be tailored to patient risk and clinical status. When complete revascularization fails, mechanisms such as stent thrombosis, in-stent restenosis, graft failure, and progression of untreated coronary disease should be identified; intravascular imaging has an important role in guiding repeat revascularization. Comprehensive CCS management should also address complications, including heart failure, ventricular arrhythmias, and secondary valvular disease, through a multidisciplinary, patient-centered approach.
- Open Access
- 1 January 2026
- Published by XMLink in Korean Circulation Journal
- Vol. 56 (7) , 531-561
Korean Society of Interventional Cardiology Expert Consensus for the Management of Chronic Coronary Syndrome: Part 1
Coronary artery disease is one of the leading causes of death worldwide and represents a major health burden in Korea. Chronic coronary syndrome (CCS) encompasses the long-term and heterogeneous clinical manifestations of ischemic heart disease, ranging from obstructive epicardial disease to non-obstructive and microvascular disease. This pathophysiological heterogeneity necessitates individualized diagnostic and therapeutic strategies to prevent progression from CCS to acute coronary syndrome. Since the publication of recent CCS guidelines, new evidence has emerged regarding optimal diagnostic strategies, physiological and intravascular imaging-based assessments, and medical therapy. In addition, contemporary CCS management increasingly emphasizes multidisciplinary integration, including cardiovascular prevention, non-invasive imaging-guided decision-making, and patient-centered revascularization strategies. However, the implementation of these principles in real-world Korean clinical practice remains unclear, highlighting the need for localized, evidence-based guidance for Korean patients with CCS. This expert consensus provides a comprehensive, stepwise framework for the diagnosis, treatment, and long-term management of CCS by integrating the latest international evidence with Korean clinical data and practice patterns.
- 1 January 2026
- Published by XMLink in Korean Circulation Journal
- Vol. 56 (7) , 531-561
Open AccessKorean Society of Interventional Cardiology Expert Consensus for the Management of Chronic Coronary Syndrome: Part 1
Coronary artery disease is one of the leading causes of death worldwide and represents a major health burden in Korea. Chronic coronary syndrome (CCS) encompasses the long-term and heterogeneous clinical manifestations of ischemic heart disease, ranging from obstructive epicardial disease to non-obstructive and microvascular disease. This pathophysiological heterogeneity necessitates individualized diagnostic and therapeutic strategies to prevent progression from CCS to acute coronary syndrome. Since the publication of recent CCS guidelines, new evidence has emerged regarding optimal diagnostic strategies, physiological and intravascular imaging-based assessments, and medical therapy. In addition, contemporary CCS management increasingly emphasizes multidisciplinary integration, including cardiovascular prevention, non-invasive imaging-guided decision-making, and patient-centered revascularization strategies. However, the implementation of these principles in real-world Korean clinical practice remains unclear, highlighting the need for localized, evidence-based guidance for Korean patients with CCS. This expert consensus provides a comprehensive, stepwise framework for the diagnosis, treatment, and long-term management of CCS by integrating the latest international evidence with Korean clinical data and practice patterns.
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Cardiovascular Intervention
- Vol. 5
Korean Society of Interventional Cardiology Expert Consensus for the Management of Chronic Coronary Syndrome: Part 2
Lee SH, et al. J Cardiovasc Interv. 2026 ;5:e34. https://doi.org/10.54912/jci.2026.0019
- 1 January 2026
- Published by XMLink in Journal of Cardiovascular Intervention
- Vol. 5
Open AccessKorean Society of Interventional Cardiology Expert Consensus for the Management of Chronic Coronary Syndrome: Part 2
Lee SH, et al. J Cardiovasc Interv. 2026 ;5:e34. https://doi.org/10.54912/jci.2026.0019
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Cardiovascular Intervention
- Vol. 5
Korean Society of Interventional Cardiology Expert Consensus for the Management of Chronic Coronary Syndrome: Part 1
Lee JM, et al. J Cardiovasc Interv. 2026 ;5:e33. https://doi.org/10.54912/jci.2026.0018
- 1 January 2026
- Published by XMLink in Journal of Cardiovascular Intervention
- Vol. 5
Open AccessKorean Society of Interventional Cardiology Expert Consensus for the Management of Chronic Coronary Syndrome: Part 1
Lee JM, et al. J Cardiovasc Interv. 2026 ;5:e33. https://doi.org/10.54912/jci.2026.0018
- Open Access
- 1 January 2026
- Published by XMLink in Korean Circulation Journal
- Vol. 56
Reconsidering Radial Strategy in Cardiogenic Shock
- 1 January 2026
- Published by XMLink in Korean Circulation Journal
- Vol. 56
Open AccessReconsidering Radial Strategy in Cardiogenic Shock
- Open Access
- 5 June 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (6) , e0304843
Long-term clinical outcomes of image-guided percutaneous coronary intervention in acute myocardial infarction from the Korea Acute Myocardial Infarction Registry
Imaging modalities for percutaneous coronary intervention (PCI), such as intravascular ultrasound (IVUS) or optical coherence tomography (OCT), have increased in the current PCI era. However, their clinical benefits in acute myocardial infarction (AMI) have not been fully elucidated. This study investigated the long-term outcomes of image-guided PCI in patients with AMI using data from the Korean Acute Myocardial Infarction Registry. A total of 9,271 patients with AMI, who underwent PCI with second-generation drug-eluting stents between November 2011 and December 2015, were retrospectively examined, and target lesion failure (TLF) at 3 years (defined as the composite of cardiac death, target vessel myocardial infarction, and ischemia-driven target lesion revascularization) was evaluated. From the registry, 2,134 patients (23.0%) underwent image-guided PCI (IVUS-guided: n = 1,919 [20.6%]; OCT-guided: n = 215 patients [2.3%]). Based on propensity score matching, image-guided PCI was associated with a significant reduction in TLF (hazard ratio: 0.76; 95% confidence interval: 0.59–0.98, p = 0.035). In addition, the TLF incidence in the OCT-guided PCI group was comparable to that in the IVUS-guided PCI group (5.3% vs 4.7%, p = 0.903). Image-guided PCI, including IVUS and OCT, is associated with favorable clinical outcomes in patients with AMI at 3 years post-intervention. Additionally, OCT-guided PCI is not inferior to IVUS-guided PCI in patients with AMI.
- 5 June 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (6) , e0304843
Open AccessLong-term clinical outcomes of image-guided percutaneous coronary intervention in acute myocardial infarction from the Korea Acute Myocardial Infarction Registry
Imaging modalities for percutaneous coronary intervention (PCI), such as intravascular ultrasound (IVUS) or optical coherence tomography (OCT), have increased in the current PCI era. However, their clinical benefits in acute myocardial infarction (AMI) have not been fully elucidated. This study investigated the long-term outcomes of image-guided PCI in patients with AMI using data from the Korean Acute Myocardial Infarction Registry. A total of 9,271 patients with AMI, who underwent PCI with second-generation drug-eluting stents between November 2011 and December 2015, were retrospectively examined, and target lesion failure (TLF) at 3 years (defined as the composite of cardiac death, target vessel myocardial infarction, and ischemia-driven target lesion revascularization) was evaluated. From the registry, 2,134 patients (23.0%) underwent image-guided PCI (IVUS-guided: n = 1,919 [20.6%]; OCT-guided: n = 215 patients [2.3%]). Based on propensity score matching, image-guided PCI was associated with a significant reduction in TLF (hazard ratio: 0.76; 95% confidence interval: 0.59–0.98, p = 0.035). In addition, the TLF incidence in the OCT-guided PCI group was comparable to that in the IVUS-guided PCI group (5.3% vs 4.7%, p = 0.903). Image-guided PCI, including IVUS and OCT, is associated with favorable clinical outcomes in patients with AMI at 3 years post-intervention. Additionally, OCT-guided PCI is not inferior to IVUS-guided PCI in patients with AMI.